Business Wire

CA-C3.AI

Share
C3.ai Launches C3.ai COVID-19 Grand Challenge

C3.ai , a leading enterprise artificial intelligence (AI) software provider for accelerating digital transformation, today welcomes data scientists, developers, researchers, and creative thinkers from around the world to participate in the C3.ai COVID-19 Grand Challenge . The competition invites participants to leverage data science techniques in new and innovative ways to generate insights that previously were neither apparent nor achievable.

“The C3.ai COVID-19 Grand Challenge represents an opportunity to inform decision makers at the local, state, and federal levels and transform the way the world confronts this pandemic,” said Thomas M. Siebel, CEO of C3.ai. “As with the C3.ai COVID-19 Data Lake and the C3.ai Digital Transformation Institute , this initiative will tap our community’s collective IQ to make important strides toward necessary, innovative solutions that will help solve a global crisis.”

What Makes a Great Solution

In response to the acute challenges the world faces, the judging panel will prioritize data science projects that help us understand and mitigate the spread of the virus; improve the response capabilities of the medical community; minimize the impact of this disease on society; and help policymakers navigate responses to COVID-19.

Projects may address, but are not limited to:

  • Applying machine learning and other AI methods to mitigate the spread of the COVID-19 pandemic
  • Genome-specific COVID-19 medical protocols, including precision medicine of host responses
  • Biomedical informatics methods for drug design and repurposing
  • Design and sharing of clinical trials for collecting data on medications, therapies, and interventions
  • Modeling, simulation, and prediction for understanding COVID-19 propagation and efficacy of interventions
  • Logistics and optimization analysis for design of public health strategies and interventions
  • Rigorous approaches to designing sampling and testing strategies
  • Data analytics for COVID-19 research harnessing private and sensitive data
  • Improving societal resilience in response to the spread of the COVID-19 pandemic
  • Broader efforts in biomedicine, infectious disease modeling, response logistics and optimization, public health efforts, tools, and methodologies around the containment of rising infectious diseases and response to pandemics.

Award Criteria

A panel of judges will evaluate submissions on the extent to which they derive insights, leveraging data science techniques (e.g., statistical analyses, AI/ML algorithms, optimization approaches, etc.) that were not obvious before.

  • Pat House, Vice Chairman, C3.ai
  • Mike Callagy, County Manager, County of San Mateo
  • Richard Levin, Board of Directors, C3.ai and Former President Emeritus, Yale University
  • S. Shankar Sastry, Co-Director, C3.ai Digital Transformation Institute and Professor of Electrical Engineering & Computer Sciences, UC Berkeley
  • Zico Kolter, Associate Professor of Computer Science, Carnegie Mellon University

The competition is now open with a registration deadline of Oct. 25 and a submission deadline of Nov. 18, 2020. To learn more about how to submit proposals, please visit https://c3.ai/grand-challenge/ .

By Dec. 9, 2020, C3.ai will announce seven competition winners and award $200,000 in cash prizes to the honorees.

  • Prizes – There will be one Grand Prize of $100,000, two second-place awards of $25,000 each, and four third-place awards of $12,500 each.
  • Publication The winners will have their work published by C3.ai.

C3.ai COVID-19 Data Lake Expands

The C3.ai™ COVID-19 Data Lake , launched in April 2020, continues to expand and now consists of 40 unique datasets, making it the largest unified, federated image of COVID-19 data in the world. Researchers and developers worldwide can access this free, open-source resource to build models, run analytics, develop tools, and more, without the time and effort of data wrangling.

As part of the C3.ai COVID-19 Grand Challenge, applicants will be required to use the C3.ai COVID-19 Data Lake as a resource to generate new and innovative solutions.

The latest datasets to be integrated into the Data Lake include:

For additional information about the C3.ai COVID-19 Data Lake, please visit: https://c3.ai/covid

To learn more about the C3.ai COVID-19 Grand Challenge, please visit https://c3.ai/grand-challenge/ .

About C3.ai

C3.ai is a leading AI software provider for accelerating digital transformation. C3.ai delivers the C3 AI® Suite for developing, deploying, and operating large-scale AI, predictive analytics, and IoT applications in addition to an increasingly broad portfolio of turnkey AI applications. The core of the C3.ai offering is a revolutionary, model-driven AI architecture that dramatically enhances data science and application development.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye